1167055-33-5 Usage
Uses
Used in Pharmaceutical and Agrochemical Synthesis:
7-Fluoro-5-nitro-1H-indole is utilized as a key intermediate in the synthesis of various bioactive compounds, including pharmaceuticals and agrochemicals. Its unique structural features, such as the nitro and fluorine atoms, contribute to the development of novel and effective molecules with therapeutic and pesticidal properties.
Used in Antibacterial and Antifungal Applications:
Due to the presence of the nitro group, 7-fluoro-5-nitro-1H-indole exhibits potential antibacterial and antifungal activities. It can be employed as an active ingredient in the development of new antimicrobial agents to combat drug-resistant infections and control fungal pathogens in various settings.
Used in Research and Development:
7-Fluoro-5-nitro-1H-indole plays a crucial role in research and development, particularly in the synthesis of new compounds with potential therapeutic applications. Its versatile chemical properties allow for the exploration of its anti-cancer and anti-inflammatory activities, paving the way for the discovery of novel treatments for various diseases.
Used in Drug Design and Optimization:
As a versatile chemical compound, 7-fluoro-5-nitro-1H-indole can be incorporated into drug design and optimization processes. Its unique structural features can be leveraged to improve the pharmacokinetic and pharmacodynamic properties of drug candidates, enhancing their efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 1167055-33-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,7,0,5 and 5 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1167055-33:
(9*1)+(8*1)+(7*6)+(6*7)+(5*0)+(4*5)+(3*5)+(2*3)+(1*3)=145
145 % 10 = 5
So 1167055-33-5 is a valid CAS Registry Number.
1167055-33-5Relevant articles and documents
5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES
-
, (2017/09/27)
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
GPR119 AGONIST
-
Page/Page column 41, (2012/07/27)
A compound represented by the formula (II) is a GPR119 agonist, and is used as an agent for treating diabetes: wherein each of R23, R24, and R25 is hydrogen, halogen, C1-8 alkyl, C1-8 alkoxy, C1-
